XC
TAK icon

XY Capital’s Takeda Pharmaceutical TAK Stock Holding History

XY Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,033
Closed -$2.93M – 306
2025
Q3 		$2.93M Buy
+200,033
New +$2.97M 1.54% 16
2025
Q2 		– Sell
-95,830
Closed -$1.42M – 194
2025
Q1 		$1.42M Sell
95,830
-66,872
-41% -$937K 0.4% 62
2024
Q4 		$2.15M Sell
162,702
-1,784
-1% -$24.5K 1.04% 25
2024
Q3 		$2.34M Sell
164,486
-179,563
-52% -$2.55M 0.8% 24
2024
Q2 		$4.45M Buy
344,049
+121,771
+55% +$1.61M 2.81% 7
2024
Q1 		$3.09M Sell
222,278
-542,859
-71% -$7.89M 1.38% 22
2023
Q4 		$10.9M Buy
765,137
+621,440
+432% +$8.82M 6.38% 3
2023
Q3 		$2.22M Buy
143,697
+65,666
+84% +$1.02M 1.28% 20
2023
Q2 		$1.23M Buy
+78,031
New +$1.28M 0.88% 38

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XY Capital's TAK Position: Q4 2025 in Review

XY Capital sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 200,033 shares — an estimated $2.93M sold.

XY Capital first reported a position in TAK in Q2 2023 and held it in 9 quarters. The position peaked at $10.9M in Q4 2023. 348 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • XY Capital reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • XY Capital sold 200,033 Takeda Pharmaceutical shares in Q4 2025, an estimated $2.93M.
  • XY Capital first reported a position in Takeda Pharmaceutical in Q2 2023 and held it in 9 quarters.
  • XY Capital's Takeda Pharmaceutical position peaked at $10.9M in Q4 2023.
  • 348 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on XY Capital's 13F filing for Q4 2025, filed 12 Feb 2026.